Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and
safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab
in the first-line setting. The population will consist of adults with PD-L1 positive
recurrent or metastatic HNSCC.